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Introduction {#s1}
============

Stringent flammability standards set in the state of California resulted in the widespread use of chemical flame retardants in commercial products ([@c7]). Of these, the polybrominated diphenyl ethers (PBDEs) were among the most abundantly used; however, due their toxicity and bioaccumulative properties, they were phased out of commerce. As such, industry was required to find alternatives such as the proprietary mixture Firemaster® 550 (FM550), which is used in commercial products including furniture, textiles, and electronics ([@c2]; [@c33]).

FM550 is composed of four different compounds: *bis*(2-ethylhexyl)-2,3,4,5-tetrabromophthalate (TBPH) (8%), 2-ethylhexyl-2,3,4,5-tetrabromobenzoate (TBB) (30%), triphenyl phosphate (TPP) (17%), and isopropylated triphenyl phosphates (IPTPs) (45%) ([@c33]). The IPTPs consist of a mixture of mono-isopropylphenyl, diphenyl-phosphate, di-isopropylphenyl, phenyl-phosphate, and tris-isopropylphenyl-phosphate in various proportions ([@c28]). Measurement of the FM550 metabolites diphenyl-phosphate (DPHP) and isopropyl-diphenyl-phosphate (ip-DPHP) in urine confirmed that exposure to the chemical mixture FM550 is ubiquitous ([@c13]). In addition, recent studies show that some of the FM550 components concentrations can reach $15,030\,\text{ng}/g$ in house dust ([@c33]) and that the metabolite ip-DPHP is ubiquitous in the urine of children at concentrations up to $24\,\text{ng}/{mL}$ ([@c13]).

A few studies suggest that FM550 and its components have metabolic effects and act as environmental obesogens. For example, in a rodent model, perinatal and lactational exposure to FM550 induced behavioral and endocrine effects, increased adipose mass, and induced insulin resistance in the offspring ([@c27]). In addition, a study in murine stem cells showed that the FM550 components TPP and IPTP divert osteogenesis to the adipogenesis pathway through activation of peroxisome proliferator-activated receptor $\gamma$ ($\text{PPAR}\gamma$) ([@c29]).

Although aforementioned studies ([@c27]; [@c29]) suggest that FM550 is an endocrine disruptor and an environmental obesogen in murine cell cultures and animal models, little is known regarding its effects on human health and obesity. Primary human preadipocytes are a relevant tool to test the ability of chemicals to induce adipogenesis in human specimens and hence can identify a potential role for these chemicals to cause metabolic effects in humans ([@c3]; [@c5]). Previous work showed that the transcriptional cascade differs in human and murine differentiating preadipocytes ([@c35], [@c34]). This suggests that chemicals have potentially different specific targets in human cells compared with mouse cells. Further, human preadipocytes have different requirements for optimal differentiation compared with the mouse models ([@c35]). One major difference is the requirement of clonal expansion for the murine cell model (3T3-L1) but not for the human primary preadipocytes ([@c15]; [@c39]). In addition, human primary preadipocytes require both dexamethasone (glucocorticoid agonist) and troglitazone (PPARG agonist) to induce differentiation ([@c15]). As such, this model presents us with the opportunity to investigate whether the chemicals of interest are acting through PPARG activation or through the glucocorticoid pathway. Conversely, murine 3T3-L1 preadipocytes differentiate with either dexamethasone or a PPARG agonist ([@c1]). Finally, human preadipocytes are primary cells, and therefore provide an *in vitro* model that is more relevant to the human condition and relevant for obesogen screening.

The purpose of this study was to determine the effects of FM550 and its individual components on adipogenesis in human primary preadipocytes, and to explore modes of action through analysis of global transcriptomic response to these chemicals. We show that FM550 and its two major components, TPP and IPTP, induce adipogenesis in human primary cells. Furthermore, global gene expression analysis revealed that pathways other than PPARG may also be involved in the adipogenic changes induced in differentiating human cells in response to FM550 components.

Materials and Methods {#s2}
=====================

Reagents {#s2.1}
--------

Chemicals were purchased from the following manufacturers: human insulin (Roche Diagnostics, Indianapolis, IN, USA); 3-isobutyl-1-methylxanthine (IBMX), dexamethasone (DEX), troglitazone, triphenyl phosphate (TPP), and dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Oakville, Ontario, Canada); 2-ethylhexyl-2,3,4,5-tetrabromobenzoate (TBB) and *bis*(2-ethylhexyl)-2,3,4,5-tetrabromophthalate (Toronto Research Chemicals, Toronto, Ontario, Canada). Isopropylated triphenyl phosphate (IPTP) was a generous gift from W. Casey (National Institute of Environmental Health Sciences, National Institutes of Health in the United States). Analysis of the IPTP mixture was hampered by the lack of availability of pure standards for the various congeners suspected to be present. By comparing mass estimates of the whole molecules (from positive chemical ionization analyses) with those of molecular fragments (from electron impact mode analyses) we estimate that the majority of the material is composed of three congeners. These were triphenyl phosphate ($\text{TPP}\, \sim 18\%$); monoisopropylphenyl, diphenylphosphate ($\text{mITP}\, \sim 55\%$); and di(isopropylphenyl), phenylphosphate ($\text{dITP}\, \sim 25\%$). In addition, there was a small amount of tris(isopropylphenyl)phosphate present in the test material, but at a substantially lower concentration ($\sim 1.5\%$). Firemaster® 550 (FM550) was a generous gift from B. Chittam (Wellington Laboratories, Guelph, Ontario, Canada).

Culture and Differentiation of Human Primary Subcutaneous Preadipocytes {#s2.2}
-----------------------------------------------------------------------

Primary human subcutaneous preadipocytes (ZenBio, Inc., Research Triangle Park, NC, USA) from female donors ages 25, 38, 40, 39, and 34 y with body mass indices of 18.8, 21.6, 23.3, 22.6, 21.5 (${{kg}/m}^{2}$) and who were of several ethnicities (one Caucasian, two Hispanic, one Asian, and one unknown) were taken from thigh, back, abdomen, and flank depots and differentiated as previously described ([@c4]) with modifications. Briefly, human primary preadipocytes were seeded in six-well dishes in subcutaneous preadipocyte media (PM-1, Zenbio Inc.), containing 10% fetal calf serum (Wisent, Montreal, Quebec, Canada). When cells reached confluence (day 0), they were treated with $100\,\text{nM}$ insulin (I) and $500\;\mu M$ IBMX (M) until day 4, with a media change on day 2. From day 4 onward, cells received insulin with media changes on days 4 and 8. For the positive control (MIDT), where the cells require both dexamethasone and troglitazone, dexamethasone (D) ($1\;\mu M$) was added from days 0 to 14 and troglitazone (T) ($5\;\mu M$) from days 2 to 14 in addition to MI. Treatments with the chemicals of interest were performed as follows: *a*) when the chemicals were tested for their ability to replace troglitazone, the cells were treated with dexamethasone from day 0 and the test chemical ($0–200\;\mu M$ FM550, $0–200\;\mu M$ IPTP, $0–20\;\mu M$ TPP, $0–20\;\mu M$ TBPH, $0–20\;\mu M$ TBB) from day 2, with media replacements on days 4 and 8 (MID condition); *b*) when the chemicals were to replace dexamethasone, the test chemical was added from day 0, and troglitazone with the test chemical were added from day 2 onward and replaced with media changes on days 2, 4, and 8 (MIT condition). IBMX and insulin were added in all treatments as described above for the MIDT condition.

Nile Red Staining of Lipids {#s2.3}
---------------------------

Primary human preadipocytes were differentiated as described above for 14 d with the indicated treatments and controls in black collagen-coated 96-well plates (Fisher Scientific, Canada). The level of differentiation was assessed using a fluorescence plate reader as follows. At day 14, cells were fixed with 4% paraformaldehyde (VWR, Canada) for 30 min followed by PBS washes. Background fluorescence was read in PBS at 485/528 for Nile red and 360/460 for DAPI. Cells were then stained with Nile red ($1\;\mu g/{mL}$) to stain for lipid droplets and DAPI ($1\;\mu g/{mL}$) to stain nuclei as previously described ([@c40]). Nile red fluorescence was read at $485/528\,\text{nm}$ (excitation/emission) in a Synergy 2 fluorescence plate reader (BioTek Instruments, Inc., Winooski, VT, USA) and DAPI staining, nuclei staining, was measured at $360/460\,\text{nm}$ . To calculate Nile red to DAPI ratios the background fluorescence was first subtracted from the readings of Nile red and DAPI at the respective wavelengths, and Nile red/DAPI ratios were calculated for each of the wells.

Western Blotting {#s2.4}
----------------

Human primary preadipocytes were seeded in six-well dishes and treated according to the differentiation protocol described above. On day 14, cells were lysed in RIPA buffer ($20\,\text{mM}$ Tris pH 7.5, $150\,\text{mM}$ NaCl, $1\,\text{mM}$ EDTA, 1% sodium deoxycholate, 2% NP-40, 0.4% SDS, 10% glycine) containing protease inhibitors (Roche Diagnostics, Laval, Quebec, Canada). Western blots were performed by probing with primary fatty acid binding protein (FABP) 4 and $\beta - \text{actin}$ ACTB antibodies (Cell Signaling Technology, Danvers, MA, USA) followed by appropriate HRP-linked secondary antibodies, and developed using Clarity Western ECL Substrate (BioRad, Hercules, CA, USA). Relative optical densities were quantified using Image Lab software (BioRad), and values of terminal differentiation markers were normalized to ACTB levels.

mRNA Extraction and Real-Time Quantitative PCR (RT-qPCR) {#s2.5}
--------------------------------------------------------

Total RNA was extracted from differentiating human primary preadipocytes, treated as previously described. Samples were taken on days 4, 6, 9, and 12 using the RNeasy Mini kit and genomic DNA was eliminated using the RNase-Free DNase Kit (Qiagen, Mississauga, Ontario, Canada). RNA was reverse transcribed using iScript cDNA Synthesis Kit (BioRad). cDNA expression levels were analyzed by the CFX96-PCR Detection System using the iQSYBR SsoFast EvaGreen Supermix (BioRad). Primer sequences for each gene are summarized in Table S1. Primer efficiencies were $\geq 90\%$ and specificity was confirmed by sequence blast and melting curve analysis. All target gene transcripts were normalized to *ACTB* expression, which was not affected by treatment. Fold inductions were calculated using time-matched, control solvent-treated samples, and the comparative CT ($\Delta\Delta\text{CT}$) method was used for data analysis.

For RNA-seq analysis, total RNA was extracted from differentiating cells treated as described above using the RNeasy Kit and genomic DNA was eliminated using the RNase-Free DNase Kit (both from Qiagen, Mississauga, Ontario, Canada). RNA was quantified and RNA quality was determined using a BioAnalyzer (Agilent Technologies, Santa Clara, CA, USA). RNA samples with A260/A280 ratios $> 1.8$ and RNA integrity numbers (RIN) $> 8.0$ were used.

Ion Proton^TM^ Sequencing (RNA-Seq) {#s2.6}
-----------------------------------

Total RNA from preadipocytes from five donors treated with MID, MITD, TPP, or IPTP was collected on day 6 of differentiation of preadipocytes, from five donors were used for RNA-Seq. Poly (A) RNA enrichment (DynaBeads® mRNA DIRECT Micro Kit, Thermo Fisher, Waltham, MA, USA) was performed for each sample on $1\;\mu g$ of total RNA. The Ion Total RNA-Seq Kit version 2 (Thermo Fisher, Waltham, MA, USA) was used to fragment and prepare the sample libraries from poly (A)--enriched samples. The 3′-end barcode adapters provided in the Ion Xpress™ RNA-Seq Barcode Kit were ligated to the ends of the fragmented libraries (each PCR product receiving its own unique barcode). Libraries were then amplified using the Platinum® PCR SuperMix High Fidelity (Thermo Fisher, Waltham, MA, USA). Each amplified library was quantified/qualified using the High Sensitivity D1000 ScreenTape Kit and the Agilent® 2,200 TapeStation Instrument. Aliquots of each library were pooled together for a total final concentration of 50 pM. Emulsion PCR and chip loading was performed on the Ion Chef with the Ion P1 HI-Q Chef kit (Thermo Fisher, Waltham, MA, USA). The chips (P1 version 3) were run on the Ion Proton using the HI-Q chemistry. The Proton™ Torrent Server version 4.3 was used to interpret the sequencing data and generate unaligned binary version of a sequence aignment map (BAM) files for each barcoded sample. Reads were trimmed to remove low quality read prefixes, and then aligned to the reference genome (GRCh38v77) using Star ([@c6]) and Bowtie ([@c21]). Following alignment, gene counting was performed with HT-Seq count (<http://www-huber.embl.de/users/anders/HTSeq/doc/count.html>) with the m parameter set to "intersection-nonempty" using the Ensembl GTF annotation (GRCh38v77). The table of counts was then imported into R (version 3.1.0; R Development Core Team) where genes that did not obtain a minimum total count of at least 0.5 reads per million within at least one dose group were removed from further analyses. The EdgeR ([@c31]) package was used for the analysis. The data was normalized with TMM ([@c32]). The calculation of differentially expressed genes was performed using a paired design and using the GLM function. The data are publically available from Sequence Read Archive (<http://www.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?view=studies>; BioProject ID SRP100037).

Biological and Pathway Analyses {#s2.7}
-------------------------------

All genes with a false discovery rate (FDR) $p < 0.05$ and $\text{fold}\,\text{change} > \pm 1.5 - \text{fold}$ compared with matched controls were considered DEGs and selected for further analyses. Biological functions, canonical pathways, and upstream regulatory molecules/networks were analyzed using Ingenuity Pathway Analysis (IPA) (Ingenuity Systems, Redwood City, CA, USA). DEGs were uploaded into IPA for functional analysis. Within IPA, a standard analytical workflow was used to identify the enriched canonical pathways, diseases, and biological functions, using adipose tissue as the target. The significance of the association between the gene expression data set and the pathways and functions in IPA was measured using IPA's built in Fischer's exact test (deemed significant if $p \leq 0.05$). (For further details see <https://www.ingenuity.com/wp-content/themes/ingenuity-qiagen/pdf/ipa/IPA-netgen-algorithm-whitepaper.pdf>).

Statistical Analyses {#s2.8}
--------------------

One-way ANOVA, followed by a Dunnett's or Tukey's post hoc test were used when comparing multiple means within an experiment. Student's *t*-test was used when comparing two means. Significance was defined as $p \leq 0.05$. Statistical analyses were performed using SigmaPlot software version 12.5 (San Jose, CA, USA) or GraphPad Prism version 7 (La Jolla, CA, USA).

Results {#s3}
=======

Effects of FM550, IPTP, and TPP on Adipogenesis in Human Primary Preadipocytes {#s3.1}
------------------------------------------------------------------------------

Previous studies in murine cell models have shown that FM550, and its component TPP, increased adipogenesis through direct activation of $\text{PPAR}\gamma$ ([@c29]). We investigated whether this is also true for human primary preadipocytes by assessing lipid accumulation and expression levels of adipogenic markers. Two conditions were used to establish whether FM550 and its components induce differentiation in human primary preadipocytes and if they act only through PPARG in this model system. One condition was a differentiation protocol where the chemicals of interest were added in the presence of IBMX, insulin, and dexamethasone (MID). The second condition was when the chemicals were added to human preadipocytes exposed to IBMX, insulin, and troglitazone (MIT). In positive controls, IBMX, insulin, dexamethasone, and troglitazone were added (MIDT).

Lipid accumulation was measured on day 14 by Nile red fluorescence values normalized to DAPI fluorescence. Human primary preadipocytes treated with the FM550 mixture exhibited a dose-dependent increase in lipid accumulation, with statistical significance achieved in the MID condition at $200\;\mu M$ FM550, where a 4-fold increase as compared with MID alone was achieved ([Figure 1A](#f1){ref-type="fig"}). TPP also induced a 4-fold increase in lipid accumulation relative to MID controls at $20\;\mu M$ ([Figure 1B](#f1){ref-type="fig"}). An increasing trend was also seen with TPP treatment in the MIT condition, but this was not statistically significant. IPTP treatment induced a significant $\sim 4 - \text{fold}$ increase in lipid accumulation by Nile red staining at both 10 and $20\;\mu M$, as compared with the MID condition ([Figure 1C](#f1){ref-type="fig"}). An increasing trend was also observed in the MIT condition; however, this increase did not reach statistical significance ([Figure 1C](#f1){ref-type="fig"}). TBB and TBPH did not increase lipid accumulation, although an increasing trend was observed in the TBB dose--response curve ([Figure 1D,E](#f1){ref-type="fig"}). As expected, the positive control MIDT increased lipid accumulation (see Figure S1).

![Effects of Firemaster 550®, and its components TPP and IPTP, on lipid accumulation in differentiating human preadipocytes. Human primary preadipocytes were induced to differentiate for 14 d in the presence of MI and $1\;\mu M$ dexamethasone (MID) or MI and $5\;\mu M$ troglitazone (MIT) supplemented with either FM550 ($0–200\;\mu M$) or its components (TPP, IPTP, TBB, and TBPH; $0–20\;\mu M$). At day 14 of differentiation, lipid accumulation was quantified by Nile red staining normalized to DAPI. Data from all treatments, normalized to their respective control condition (MID or MIT), are graphically presented as $\text{mean} \pm \text{SEM}$ of four separate donor samples. \*$p < 0.05$ compared with respective controls, as assessed by one-way ANOVA with Dunnett's post hoc tests.](EHP1318_f1){#f1}

Effects of FM550, IPTP, and TPP on FABP4 Protein Expression in the Presence of Dexamethasone {#s3.2}
--------------------------------------------------------------------------------------------

To further assess the extent of adipocyte differentiation and to delineate whether in human preadipocytes FM550 and its components up-regulate the expression of known PPARG targets, protein levels of the mature adipocyte marker, FABP4, were measured by Western blotting. In the presence of MID, $200\;\mu M$ FM550 significantly increased FABP4 expression by $\sim 4 - \text{fold}$ compared with MID controls; however, this effect was not observed when the mixture was added in the presence of MIT ([Figure 2A](#f2){ref-type="fig"}). This may be partially due to the higher background in the presence of troglitazone given that FABP4 is a known target of PPARG. Similarly, $20\;\mu M$ TPP induced a 6-fold increase in FABP4 expression relative to MID ([Figure 2B](#f2){ref-type="fig"}), although increasing trends were observed at lower concentrations but did not reach statistical significance. Again, this effect was not observed in the presence of MIT ([Figure 2B](#f2){ref-type="fig"}). Remarkably, IPTP treatment induced an increase not only at $20\;\mu M$ (10-fold), but also at $10\;\mu M$ (5-fold) compared with MID controls ([Figure 2C](#f2){ref-type="fig"}). Note that, at equivalent concentrations (10 and $20\;\mu M$), IPTP induced a higher expression of FABP4 relative to TPP treatment ([Figure 2B,C](#f2){ref-type="fig"}). TBPH and TBB did not affect FABP4 protein expression in the presence of either MID or MIT (data not shown).

![Effects of Firemaster 550®, and its components TPP and IPTP, on FABP4 protein expression in the presence of dexamethasone or troglitazone. Human primary preadipocytes were induced to differentiate for 14 d in the presence of MI and $1\;\mu M$ dexamethasone (MID) or MI and $5\;\mu M$ troglitazone (MIT) supplemented with either FM550 ($0–200\;\mu M$) (*A*), or its components (TPP and IPTP; $0–20\;\mu M$) (*B*, *C*). Equal amounts of solubilized cellular proteins were separated by SDS-PAGE and immunoblotted with antibodies against FABP4 and ACTB as a loading control. Densitometric data from four separate donor samples, normalized to loading control, are graphically presented as $\text{means} \pm \text{SEM}$. \*$p < 0.05$ compared with respective controls, as assessed by one-way ANOVA with Dunnett's post hoc tests.](EHP1318_f2){#f2}

Effects of TPP and IPTP on the mRNA Expression of Transcriptional Regulators of Adipogenesis and Adipogenic Markers in Human Primary Preadipocytes {#s3.3}
--------------------------------------------------------------------------------------------------------------------------------------------------

Our initial findings indicated that the MID condition was optimal for FM550-induced human adipocyte differentiation and that the FM550 components TPP and IPTP-containing 18% TPP were adipogenic. Therefore, the temporal changes in the mRNA levels of transcription factors and differentiation markers of adipogenesis were assessed in response to $20\;\mu M$ TPP and $20\;\mu M$ IPTP relative to MID controls.

First we assessed the mRNA levels of master regulators of adipogenesis, *PPARG* and CCAT enhancing binding protein $\alpha$ (*CEBPA*). *PPARG* expression was increased through the course of differentiation in TPP- and IPTP-treated cells relative to MID controls ([Figure 3A](#f3){ref-type="fig"}). *CEBPA* levels were also increased following treatment with both TPP and IPTP during adipogenesis compared with MID controls ([Figure 3B](#f3){ref-type="fig"}). In the TPP-treated cells, this increase was observed earlier in differentiation; however, similar levels were attained by both chemicals by the end of differentiation ([Figure 3E](#f3){ref-type="fig"}). For the mature adipocyte markers, both *FABP4* and lipoprotein lipase (*LPL*) mRNA expression levels were increased with adipogenesis in response to both TPP and IPTP relative to MID control. Again, although the increase with IPTP was delayed relative to TPP, both components led to similar levels by the end of differentiation ([Figure 3C, D](#f3){ref-type="fig"}). Perilipin (*PLIN*) mRNA expression, indicative of lipid droplet formation, was also up-regulated by TPP and IPTP during adipogenesis as compared with MID control. TPP increased *PLIN* levels as early as day 6, and the levels were maintained throughout the differentiation process. However, the increase by IPTP was to a lower extent than in TPP-treated cells and reached statistical significance only at day 9 ([Figure 2E](#f2){ref-type="fig"}). We also measured the mRNA levels of the lipogenic transcription factor, sterol regulatory element binding transcription factor 1 (*SREBF1*), and found that both TPP and IPTP increased its expression during differentiation as compared with MID ([Figure 3F](#f3){ref-type="fig"}). As expected, the positive control (i.e., MIDT) increased the expression of *PPARG*, *CEBPA*, *FABP4*, *LPL*, *PLIN*, and *SREBF1* throughout the differentiation process as illustrated in Figure S2.

![Effects of TPP and IPTP on the mRNA expression levels of transcriptional regulators of adipogenesis and adipogenic markers in differentiating human preadipocytes. Human primary preadipocytes were induced to differentiate for 4, 6, 9, and 12 d in the presence of $1\;\mu M$ dexamethasone (MID) supplemented with either TPP ($20\;\mu M$) or IPTP ($20\;\mu M$). RNA was isolated and the mRNA levels of adipogenic markers, PPARG (*A*), CEBPA (*B*), FABP4 (*C*), LPL (*D*), PLIN1 (*E*), and SREBF1 (*F*) were quantified by real-time qPCR. Levels were normalized to endogenous ACTB mRNA, and expressed as a fold over the control condition (MID) for each time point. Results from five separate donor samples are graphically presented as $\text{means} \pm \text{SEM}$. \#$p < 0.05$ for TPP-treated cells, and \*$p < 0.05$ for IPTP-treated cells compared with MID controls, as assessed by one-way ANOVA with Dunnett's post hoc tests.](EHP1318_f3){#f3}

Transcriptional Profiling of Human Primary Preadipocytes Treated with TPP, IPTP, and Troglitazone {#s3.4}
-------------------------------------------------------------------------------------------------

To further investigate the effects of TPP and IPTP on the adipogenic pathway, human primary preadipocytes were differentiated in the presence of MID supplemented with $20\;\mu M$ TPP, $20\;\mu M$ IPTP, or $5\;\mu M$ troglitazone. At day 6 of differentiation, RNA was collected from five donors and used for RNA-seq. Overall, TPP and IPTP treatments resulted in 380 and 713 DEGs, respectively, whereas troglitazone treatment resulted in 3,277 ([Figure 4](#f4){ref-type="fig"}). Of the DEGs affected by TPP, only 5.8% were distinct; in contrast, 29% of DEGs affected by IPTP were unique. Most of the genes up-regulated by TPP (84%) were in common with troglitazone; whereas only 65% of the IPTP affected genes were also affected by troglitazone. Hierarchical cluster analysis of the fold changes for all DEGs from IPTP, troglitazone, and TPP shows that TPP- and IPTP-induced expression profiles cluster together and apart from troglitazone, indicating that they more closely resemble each other than the troglitazone-treatment group ([Figure 4B](#f4){ref-type="fig"}). In addition, pairwise analysis using fold changes of the common genes shows that TPP-induced expression profiles are more strongly correlated with troglitazone and IPTP ($\text{correlation} = 0.87$ and 0.86, respectively), than IPTP is correlated with troglitazone ($\text{correlation} = 0.75$). All correlations are significant with a *p*-value of $< 0.00001.$ Overall, this analysis demonstrates that the DEGs in common across the treatments are highly correlated, and that IPTP is less similar to troglitazone than TPP. The top 10 up- and down-regulated DEGs affected by TPP, IPTP, and troglitazone are listed in [Table 1](#t1){ref-type="table"}. [Table 1](#t1){ref-type="table"} shows that 45% of the top DEGs were common between TPP and IPTP, 20% of the top DEGs in TPP-treated cells were in common with troglitazone, and only 5% of the top DEGs in IPTP-treated cultures were in common with troglitazone.

![Differentially expressed genes (DEGs) affected by TPP, IPTP, and troglitazone. Human primary preadipocytes were differentiated in the presence of MID supplemented with $20\;\mu M$ TPP, $20\;\mu M$ IPTP, or $5\;\mu M$ troglitazone. At day 6 of differentiation, RNA was collected from five donors and used for RNA-seq analysis. The overlap of significant ($- 1.5 \leq \text{fold}\,\text{change} \geq 1.5$, FDR $p < 0.05$) DEGs between all treatments are depicted in a Venn diagram (*A*). Venn diagrams were produced using the on-line tool Venny (<http://bioinfogp.cnb.csic.es/tools/venny>/). (*B*) Hierarchical cluster analysis of the fold change for all DEGs from IPTP, troglitazone, TPP having an FDR of $p < 0.05$ and fold change $> 1.5$. The distance is metric $1 -$ the Spearman correlation, values greater than 5 were truncated strictly for the color scale.](EHP1318_f4){#f4}

###### 

Top 10 differentially expressed genes in differentiating human primary preadipocytes.

Table 1 lists gene symbols in the first column; the corresponding gene names, GO biological process, fold changes, and FDR are listed in the other columns.

  Gene symbol    Gene name                                                     GO biological process                                                              Fold change   FDR (*p*-value)
  -------------- ------------------------------------------------------------- ---------------------------------------------------------------------------------- ------------- -----------------
  TPP                                                                                                                                                                           
   *ITIH1*       Inter-alpha-trypsin inhibitor heavy chain 1                   Hyaluronan metabolic process                                                       7.9           $< 0.0001$
   *PCK1*        Phosphoenolpyruvate carboxykinase 1                           Glucose metabolic process                                                          7.1           $< 0.0001$
   *FABP4*       Fatty acid binding protein 4                                  Cholesterol homeostasis                                                            6.6           $< 0.0001$
   *GPBAR1*      G-protein--coupled bile acid receptor 1                       Cell surface bile acid receptor signaling pathway                                  5.7           $< 0.0001$
   *PPP1R1A*     Protein phosphatase 1 regulatory inhibitor subunit 1A         Glycogen metabolic process                                                         5.6           $< 0.0001$
   *SLCO4C1*     Solute carrier organic anion transporter family, member 4C1   Cell differentiation                                                               5.3           $< 0.0001$
   *FNDC5*       Fibronectin type III domain-containing protein 5              Response to muscle activity                                                        4.6           $< 0.0001$
   *ADIPOQ*      Adiponectin, C1Q, and collagen domain containing              Adiponectin-activated signaling pathway                                            4.5           $< 0.0001$
   *CDHR1*       Cadherin-related family member 1                              Homophilic cell adhesion via plasma membrane adhesion molecules                    4.3           $< 0.0001$
   *ITIH5*       Inter-alpha (globulin) inhibitor H5                           Negative regulation of peptidase activity                                          4.3           $< 0.0001$
   *BPIFB4*      BPI fold containing family B member 4                         Lipid binding                                                                      $- 3.0$       0.003
   *GPR78*       G-protein--coupled receptor 78                                Adenylate cyclase-activating G-protein--coupled receptor signaling pathway         $- 2.9$       0.009
   *MYH11*       Myosin heavy chain 11                                         Elastic fiber assembly                                                             $- 2.6$       0.0006
   *AMZ1*        Archaelysin family metallopeptidase 1                         Proteolysis                                                                        $- 2.5$       $< 0.0001$
   *FBXL22*      F-box and leucine-rich repeat protein 22                      Proteasome-mediated ubiquitin-dependent protein catabolic process                  $- 2.4$       $< 0.0001$
   *RGS5*        Regulator of G-protein signaling 5                            Positive regulation of GTPase activity                                             $- 2.3$       $< 0.0001$
   *D4S234E*     Neuron-specific gene family member 1                          Positive regulation of receptor recycling                                          $- 2.3$       0.0008
   *CORIN*       Corin, serine peptidase                                       Peptide hormone processing                                                         $- 2.2$       $< 0.0001$
   *KRT18*       Keratin 18                                                    Anatomical structure morphogenesis                                                 $- 2.2$       $< 0.0001$
   *CNN1*        Calponin 1                                                    Actomyosin structure organization                                                  $- 2.1$       $< 0.0001$
                                                                                                                                                                                 
  IPTP                                                                                                                                                                           
   *SLCO4C1*     Solute carrier organic anion transporter family, member 4C1   Cell differentiation                                                               7.9           $< 0.0001$
   *TRIM63*      Tripartite motif containing 63                                Protein ubiquitination                                                             6             $< 0.0001$
   *ABCG1*       ATP-binding cassette subfamily G member 1                     Cholesterol metabolic process                                                      5.9           $< 0.0001$
   *ITIH1*       Inter-alpha-trypsin inhibitor heavy chain 1                   Hyaluronan metabolic process                                                       5.7           $< 0.0001$
   *FABP3*       Fatty acid binding protein 3                                  Fatty acid metabolic process                                                       4.8           $< 0.0001$
   *FNDC5*       Fibronectin type III domain containing 5                      Response to muscle activity                                                        4.9           $< 0.0001$
   *PLEKHG6*     Pleckstrin homology and RhoGEF domain containing G6           Positive regulation of GTPase activity                                             4.7           $< 0.0001$
   *RNF157*      Ring finger protein 157                                       Zinc ion binding                                                                   4.6           $< 0.0001$
   *EFNA1*       Ephrin A1                                                     Activation of MAPK activity                                                        4.6           $< 0.0001$
   *PPP1R1A*     Protein phosphatase 1 regulatory inhibitor subunit 1A         Glycogen metabolic process                                                         4.2           $< 0.0001$
   *MYH11*       Myosin heavy chain 11                                         Elastic fiber assembly                                                             $- 4.8$       $< 0.0001$
   *LBP*         Lipopolysaccharide binding protein                            Lipopolysaccharide-mediated signaling pathway                                      $- 4.5$       $< 0.0001$
   *RGS5*        Regulator of G-protein signaling 5                            Positive regulation of GTPase activity                                             $- 4.5$       $< 0.0001$
   *OXTR*        Oxytocin receptor                                             G-protein--coupled receptor signaling pathway                                      $- 4.1$       $< 0.0001$
   *KRT18*       Keratin 18                                                    Anatomical structure morphogenesis                                                 $- 3.7$       $< 0.0001$
   *DKK2*        Dickkopf WNT signaling pathway inhibitor 2                    Wnt signaling pathway                                                              $- 3.6$       $< 0.0001$
   *FBXL22*      F-box and leucine-rich repeat protein 22                      Proteasome-mediated ubiquitin-dependent protein catabolic process                  $- 3.5$       $< 0.0001$
   *CXCL5*       C-X-C motif chemokine ligand 5                                G-protein--coupled receptor signaling pathway                                      $- 3.4$       $< 0.0001$
   *CORIN*       Corin, serine peptidase                                       Peptide hormone processing                                                         $- 3.4$       $< 0.0001$
   *TLL1*        Tolloid like 1                                                Cell differentiation                                                               $- 3.2$       $< 0.0001$
                                                                                                                                                                                 
  Troglitazone                                                                                                                                                                   
   *SCN4A*       Sodium voltage-gated channel alpha subunit 4                  Regulation of ion transmembrane transport                                          261.5         $< 0.0001$
   *CD96*        CD96 molecule                                                 Cell adhesion                                                                      147.7         $< 0.0001$
   *PCK1*        Phosphoenolpyruvate Carboxykinase 1                           Glucose metabolic process                                                          121.3         $< 0.0001$
   *ADAMTS18*    ADAM metallopeptidase with thrombospondin type 1 motif 18     Proteolysis                                                                        113.0         $< 0.0001$
   *MOGAT1*      Monoacylglycerol O-acyltransferase 1                          Diacylglycerol biosynthetic process                                                107.2         $< 0.0001$
   *ADRA1A*      Adrenoceptor alpha 1A                                         G-protein--coupled receptor signaling pathway                                      98.3          $< 0.0001$
   *SCGN*        Secretagogin, EF-hand calcium binding protein                 Regulation of cytosolic calcium ion concentration                                  93.3          $< 0.0001$
   *PPP1R1A*     Protein phosphatase 1 regulatory inhibitor subunit 1A         Glycogen metabolic process                                                         67.8          $< 0.0001$
   *CDH22*       Cadherin 22                                                   Calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules   61.6          $< 0.0001$
   *ADIPOQ*      Adiponectin, C1Q, and collagen domain containing              Adiponectin-activated signaling pathway                                            56.6          $< 0.0001$
   *CCL13*       C-C motif chemokine ligand 13                                 G-protein--coupled receptor signaling pathway                                      $- 9.8$       $< 0.0001$
   *STEAP4*      STEAP4 metalloreductase                                       Iron ion homeostasis                                                               $- 6.7$       $< 0.0001$
   *PPP2R2C*     Protein phosphatase 2 regulatory subunit Bgamma               Regulation of protein phosphatase type 2A activity                                 $- 6.1$       $< 0.0001$
   *PMAIP1*      Phorbol-12-myristate-13-acetate-induced protein 1             Intrinsic apoptotic signaling pathway                                              $- 6.1$       $< 0.0001$
   *BPIFB4*      BPI fold containing family B member 4                         Lipid binding                                                                      $- 6.1$       $< 0.0001$
   *CSF3*        Colony stimulating factor 3                                   Cellular response to cytokine stimulus                                             $- 5.9$       $< 0.0001$
   *RAB27B*      RAB27B, member RAS oncogene family                            Small GTPase-mediated signal transduction                                          $- 5.9$       $< 0.0001$
   *WISP1*       WNT1 inducible signaling pathway protein 1                    Wnt signaling pathway                                                              $- 5.8$       $< 0.0001$
   *FRMPD4*      FERM and PDZ domain containing 4                              Positive regulation of synapse structural plasticity                               $- 5.4$       $< 0.0001$
   *RGCC*        Regulator of cell cycle                                       Fibroblast activation                                                              $- 5.2$       $< 0.0001$

Note: Human primary preadipocytes were differentiated in the presence of MID supplemented with $20\;\mu M$ TPP, $20\;\mu M$ IPTP, or $5\;\mu M$ troglitazone. At day 6 of differentiation, RNA was collected from five donors and used for RNA-seq analysis. The top 10 up- and down-regulated genes are shown. FDR, false discovery rate; GO, gene ontology.

Validation of Select Differentially Expressed Genes by RT-qPCR {#s3.5}
--------------------------------------------------------------

We validated some of the DEGs found in the RNA-seq analysis by RT-qPCR. Of the up-regulated genes, *FABP5*, *PLIN4*, and phosphoenolpyruvate carboxykinase 1 (*PCK1*) were increased in both TPP- and IPTP-treated cells. However, only TPP significantly increased the mRNA levels of the above genes ([Figure 5A--C](#f5){ref-type="fig"}). By contrast, other genes including ATP-binding cassette subfamily G member 1 (*ABCG1*), solute carrier organic anion transporter family, member 4C1 (*SLCO4C1*), and *FABP3* were significantly increased by IPTP and not TPP ([Figure 5D--F](#f5){ref-type="fig"}). It is possible that by adding more repeats we would have reached statistical significance for *FABP5*, *PCK1, PLIN4, ABCG1*, and *SLCO4C1* for both treatments. Some genes were equally increased by both treatments ([Figure 5G--I](#f5){ref-type="fig"}). All of these genes were up-regulated by troglitazone control (see Figure S3). Interestingly, lipopolysaccharide binding protein (*LBP*) levels were down-regulated in IPTP-treated cells, not affected by TPP exposure, and up-regulated in troglitazone positive controls ([Figure 5J](#f5){ref-type="fig"}; see also Figure S3). Further, keratin 18 (*KRT18*) levels were decreased by both TPP and IPTP; however, the expression of this gene was not changed in response to troglitazone ([Figure 5K](#f5){ref-type="fig"}; see also Figure S3).

![Validation of selected differentially expressed genes (DEGs) by RT-qPCR. Human primary preadipocytes were differentiated in the presence of MID supplemented with $20\;\mu M$ TPP or $20\;\mu M$ IPTP. At day 6 of differentiation, RNA was collected for RNA-seq analysis. The mRNA levels of select DEGs from RNA-seq analysis were quantified by RT-qPCR. Levels were normalized to endogenous ACTB mRNA, and expressed as a fold over the control condition (MID) for each treatment. Results from five separate donor samples are graphically presented as $\text{means} \pm \text{SEM}$. \*$p < 0.05$, \*\*$p < 0.01$, and \*\*\*$p < 0.001$ for TPP- and IPTP- treated samples compared with control; \#$p < 0.05$, \#\#$p < 0.01$, and \#\#\#$p < 0.001$ for TPP-treated compared with IPTP-treated samples, as assessed by one-way ANOVA with Tukey's post hoc tests.](EHP1318_f5){#f5}

Canonical Pathways and Upstream Regulators Identified in IPA's Knowledge Base in Human Primary Preadipocytes Treated with TPP and IPTP {#s3.6}
--------------------------------------------------------------------------------------------------------------------------------------

The DEGs obtained from the RNA-seq analysis of TPP, IPTP, and troglitazone treatments were analyzed using IPA to identify enrichment of canonical pathways and upstream regulators. The top canonical pathways for each treatment identified in IPA are summarized in [Table 2](#t2){ref-type="table"}. As expected, the adipogenesis pathway was significantly enriched in TPP-, IPTP-, and troglitazone-treatment groups. In addition, there were several common pathways between TPP and IPTP treatments, such as liver X receptor (LXR)/retinoid X receptor (RXR) activation, cholesterol biosynthesis I, and lipopolyscharide (LPS)/interleukin-1 (IL-1)--mediated inhibition of RXR function ([Table 2A,B](#t2){ref-type="table"}). Of these pathways, only LPS/IL-1--mediated inhibition of RXR function pathway was also in the top 20 pathways affected by troglitazone ([Table 2C](#t2){ref-type="table"}). Only 65% of the canonical pathways were common to both TPP and IPTP treatments. Some of the distinct pathways identified in TPP-treated cells were protein kinase A signaling, AMP-activated protein kinase (AMPK) signaling, and type II diabetes mellitus signaling. In the IPTP treatment, unique pathways included caveolar-mediated endocytosis signaling, clathrin-mediated endocytosis signaling, and acute phase response signaling. Of the top 20 pathways affected by IPTP and TPP treatment, several pathways overlapped and included superpathway of cholesterol biosynthesis, cholesterol biosynthesis (I, II, III), LXR/RXR activation ([Table 2A,B](#t2){ref-type="table"}). Troglitazone treatment was also associated with effects on pathways such as cAMP-mediated signaling and PXR/RXR activation, in addition to mitochondrial dysfunction and oxidative phosphorylation pathways ([Table 2C](#t2){ref-type="table"}).

###### 

Top 20 significant canonical pathways identified by IPA.

Table 2 lists IPA canonical pathways in the first column; the corresponding p-values and ratios are listed in the other columns.

  IPA canonical pathway                                                              *p*-Value    Ratio
  ---------------------------------------------------------------------------------- ------------ --------
  TPP                                                                                             
   LXR/RXR activation                                                                $< 0.0001$   0.227
   LPS/IL-1--mediated inhibition of RXR function                                     $< 0.0001$   0.109
   Superpathway of cholesterol biosynthesis                                          $< 0.0001$   0.688
   TR/RXR activation                                                                 $< 0.0001$   0.177
   Protein kinase A signaling                                                        0.009        0.0526
   Tight junction signaling                                                          0.0002       0.0909
   AMPK signaling                                                                    0.001        0.0758
   Adipogenesis pathway                                                              0.0003       0.0947
   Hepatic fibrosis/hepatic stellate cell activation                                 0.001        0.0796
   ILK signaling                                                                     0.002        0.0769
   Cholesterol biosynthesis I                                                        $< 0.0001$   0.889
   Cholesterol biosynthesis II (via 24,25-dihydrolanosterol)                         $< 0.0001$   0.889
   Cholesterol biosynthesis III (via Desmosterol)                                    $< 0.0001$   0.889
   Cellular effects of sildenafil (Viagra)                                           $< 0.0001$   0.133
   Type II diabetes mellitus signaling                                               0.0008       0.093
   G-protein--coupled receptor signaling                                             0.019        0.0552
   Cardiac $\beta - \text{adrenergic}$ signaling                                     0.001        0.0972
   cAMP-mediated signaling                                                           0.01         0.0631
   Stearate biosynthesis I (animals)                                                 $< 0.0001$   0.231
   FXR/RXR activation                                                                0.003        0.0968
                                                                                                   
  IPTP                                                                                             
   LXR/RXR activation                                                                $< 0.0001$   0.288
   Hepatic fibrosis/hepatic stellate cell activation                                 $< 0.0001$   0.159
   LPS/IL-1--mediated inhibition of RXR function                                     $< 0.0001$   0.124
   Clathrin-mediated endocytosis signaling                                           0.003        0.0917
   Superpathway of cholesterol biosynthesis                                          $< 0.0001$   0.625
   Acute phase response signaling                                                    0.003        0.0962
   Tight junction signaling                                                          0.005        0.0909
   ILK signaling                                                                     0.008        0.0855
   FXR/RXR activation                                                                0.0003       0.145
   TR/RXR activation                                                                 0.0003       0.145
   Agranulocyte adhesion and diapedesis                                              0.005        0.0978
   Cellular effects of sildenafil (Viagra)                                           0.001        0.133
   Cholesterol biosynthesis I                                                        $< 0.0001$   0.778
   Cholesterol biosynthesis II (via 24,25-dihydrolanosterol)                         $< 0.0001$   0.778
   Cholesterol biosynthesis III (via Desmosterol)                                    $< 0.0001$   0.778
   Atherosclerosis signaling                                                         0.01         0.101
   Hepatic cholestasis                                                               0.04         0.0761
   Adipogenesis pathway                                                              0.05         0.0737
   Caveolar-mediated endocytosis signaling                                           0.008        0.118
   Paxillin signaling                                                                0.03         0.0896
                                                                                                   
  Troglitazone                                                                                    
   Role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis   0.017        0.236
   Mitochondrial dysfunction                                                         $< 0.0001$   0.425
   Noradrenaline and adrenaline degradation                                          0.001        0.5
   Mitochondrial L-carnitine shuttle pathway                                         0.005        0.545
   LPS/IL-1--mediated inhibition of RXR function                                     $< 0.0001$   0.38
   cAMP-mediated signaling                                                           0.003        0.279
   Fatty acid $\beta - \text{oxidation}\,$ I                                         $< 0.0001$   0.625
   Cardiac $\beta - \text{adrenergic}$ signaling                                     0.001        0.319
   PXR/RXR activation                                                                0.028        0.295
   Agranulocyte adhesion and diapedesis                                              0.019        0.261
   Melanocyte development and pigmentation signaling                                 0.005        0.316
   Glutaryl-CoA degradation                                                          $< 0.0001$   0.9
   $\text{PPAR}\alpha/\text{RXR}\alpha$ activation                                   $< 0.0001$   0.316
   p38 MAPK signaling                                                                0.011        0.295
   Sperm motility                                                                    0.011        0.295
   Oleate biosynthesis II (animals)                                                  0.019        0.571
   Endothelin-1 signaling                                                            0.028        0.25
   Myc-mediated apoptosis signaling                                                  0.039        0.289
   Regulation of the epithelial--mesenchymal transition pathway                      0.02         0.252
   Glutathione-mediated detoxification                                               0.017        0.412

Note: Human primary preadipocytes were differentiated in the presence of MID supplemented with $20\;\mu M$ TPP, $20\;\mu M$ IPTP, or $5\;\mu M$ troglitazone. At day 6 of differentiation, RNA was collected from five donors and used for RNA-seq. Genes that had $\geq + 1.5$ or $\leq - 1.5$ a fold change were uploaded in to IPA for analysis using the adipose tissue as the target organ. The pathways were sorted by number of molecules involved and the top 20 are shown.

Using IPA we also identified potential upstream regulators of the DEGs. As expected, PPARG was identified as a common top upstream regulator in an activated state for all treatments. In addition, SREBF1, another adipogenic transcriptional regulator, was found among the top upstream regulators. Accordingly, the insulin-induced gene (INSIG) 1 and 2, proteins known to be involved in the negative regulation of SREBF1 function, were predicted to be inhibited in all treatments. The membrane-bound transcription factor site-1 protease (MBTPS1) (also known as serine protease 1: S1P), a serine protease involved in SREBF1 activation, was predicted to be activated in all treatments as expected although not always in the top 20 ([@c14]). By contrast, the transcription factor Krüppel-like factor (KLF) 15, known to be involved in adipocyte differentiation ([@c24]), was predicted to be active only in TPP and troglitazone treatments but not IPTP ([Table 3](#t3){ref-type="table"}). Furthermore, CEBPA, another important transcription factor in adipogenesis ([@c20]) was found as an upstream regulator in TPP and troglitazone treatments (not in the top 20), but not IPTP. Finally, lamin B1 (LMNB1), a matrix protein involved in cytoskeletal organization and adipogenesis ([@c38]), was predicted to be inhibited by IPTP but not TPP or troglitazone treatment.

###### 

Top 20 upstream regulators identified by IPA.

Table 3 lists upstream regulator in the first column; the corresponding molecule type, predicted activation state, activation z-score, and p-values are listed in the other columns.

  Upstream regulator   Molecule type                       Predicted activation state   Activation *z*-score   *p*-Value
  -------------------- ----------------------------------- ---------------------------- ---------------------- ------------
  TPP                                                                                                           
   PPARG               Ligand-dependent nuclear receptor   Activated                    5.895                  $< 0.0001$
   SREBF1              Transcription regulator             Activated                    5.424                  $< 0.0001$
   SCAP                Other                               Activated                    4.618                  $< 0.0001$
   CEBPA               Transcription regulator             Activated                    3.652                  $< 0.0001$
   NR1H3               Ligand-dependent nuclear receptor   Activated                    3.546                  $< 0.0001$
   PPARGC1A            Transcription regulator             Activated                    3.465                  $< 0.0001$
   ATP7B               Transporter                         Activated                    3.464                  $< 0.0001$
   PPARGC1B            Transcription regulator             Activated                    3.248                  $< 0.0001$
   KLF15               Transcription regulator             Activated                    2.905                  $< 0.0001$
   NR1H2               Ligand-dependent nuclear receptor   Activated                    2.865                  $< 0.0001$
   INSIG1              Other                               Inhibited                    $- 4.967$              $< 0.0001$
   POR                 Enzyme                              Inhibited                    $- 3.069$              $< 0.0001$
   ELOVL5              Enzyme                              Inhibited                    $- 2.976$              $< 0.0001$
   EPAS1               Transcription regulator             Inhibited                    $- 2.969$              $< 0.0001$
   INSIG2              Other                               Inhibited                    $- 2.934$              $< 0.0001$
   ASXL1               Transcription regulator             Inhibited                    $- 2.646$              $< 0.0001$
   TNF                 Cytokine                            Inhibited                    $- 2.620$              $< 0.0001$
   MKL1                Transcription regulator             Inhibited                    $- 2.591$              $< 0.0001$
   LEP                 Growth factor                       Inhibited                    $- 2.480$              $< 0.0001$
   PML                 Transcription regulator             Inhibited                    $- 2.462$              $< 0.0001$
                                                                                                                
  IPTP                                                                                                          
   SREBF1              Transcription regulator             Activated                    4.43                   $< 0.0001$
   PPARG               Ligand-dependent nuclear receptor   Activated                    4.20                   $< 0.0001$
   SCAP                Other                               Activated                    4.05                   $< 0.0001$
   NR1H3               Ligand-dependent nuclear receptor   Activated                    3.70                   $< 0.0001$
   ATP7B               Transporter                         Activated                    3.32                   $< 0.0001$
   PPARGC1B            Transcription regulator             Activated                    2.93                   $< 0.0001$
   MBTPS1              Peptidase                           Activated                    2.43                   $< 0.0001$
   PPARD               Ligand-dependent nuclear receptor   Activated                    2.38                   $< 0.0001$
   FAS                 Transmembrane receptor              Activated                    2.35                   $< 0.0001$
   NR1H2               Ligand-dependent nuclear receptor   Activated                    2.23                   $< 0.0001$
   INSIG1              Other                               Inhibited                    $- 4.64$               $< 0.0001$
   EPAS1               Transcription regulator             Inhibited                    $- 3.08$               $< 0.0001$
   ELOVL5              Enzyme                              Inhibited                    $- 2.98$               $< 0.0001$
   MKL1                Transcription regulator             Inhibited                    $- 2.94$               $< 0.0001$
   IKBKB               Kinase                              Inhibited                    $- 2.84$               $< 0.0001$
   TGFB1               Growth factor                       Inhibited                    $- 2.83$               $< 0.0001$
   INSIG2              Other                               Inhibited                    $- 2.76$               $< 0.0001$
   POR                 Enzyme                              Inhibited                    $- 2.75$               $< 0.0001$
   LEP                 Growth factor                       Inhibited                    $- 2.48$               $< 0.0001$
   LMNB1               Other                               Inhibited                    $- 2.43$               $< 0.0001$
                                                                                                                
  Troglitazone                                                                                                  
   PPARG               Ligand-dependent nuclear receptor   Activated                    6.706                  $< 0.0001$
   PPARA               Ligand-dependent nuclear receptor   Activated                    6.302                  $< 0.0001$
   PPARGC1A            Transcription regulator             Activated                    6.283                  $< 0.0001$
   SREBF1              Transcription regulator             Activated                    5.048                  $< 0.0001$
   SCAP                Other                               Activated                    4.942                  $< 0.0001$
   RB1                 Transcription regulator             Activated                    4.767                  $< 0.0001$
   KLF15               Transcription regulator             Activated                    4.712                  $< 0.0001$
   INSR                Kinase                              Activated                    4.667                  $< 0.0001$
   PPARGC1B            Transcription regulator             Activated                    4.223                  $< 0.0001$
   PNPLA2              Enzyme                              Activated                    3.763                  $< 0.0001$
   RICTOR              Other                               Inhibited                    $- 5.182$              $< 0.0001$
   INSIG1              Other                               Inhibited                    $- 5.099$              $< 0.0001$
   TNF                 Cytokine                            Inhibited                    $- 4.972$              $< 0.0001$
   KDM5A               Transcription regulator             Inhibited                    $- 4.494$              $< 0.0001$
   TWIST1              Transcription regulator             Inhibited                    $- 3.656$              $< 0.0001$
   F2R                 G-protein--coupled receptor         Inhibited                    $- 3.359$              $< 0.0001$
   TGFB1               Growth factor                       Inhibited                    $- 3.189$              $< 0.0001$
   INSIG2              Other                               Inhibited                    $- 3.088$              $< 0.0001$
   Aldosterone         Chemical--endogenous mammalian      Inhibited                    $- 3.084$              $< 0.0001$
   HSD17B4             Enzyme                              Inhibited                    $- 2.985$              $< 0.0001$

Note: Human primary preadipocytes were differentiated in the presence of MID supplemented with $20\;\mu M$ TPP, $20\;\mu M$ IPTP, or $5\;\mu M$ troglitazone. At day 6 of differentiation, RNA was collected from five donors and used for RNA-seq. Genes that had $\geq + 1.5$ or $\leq - 1.5$ a fold change were uploaded into IPA for analysis using the adipose tissue as the target organ. The upstream regulators were sorted by *z*-score and the top 20 are shown.

Using the common and unique DEGs to the three treatments identified by the Venn diagram ([Figure 4](#f4){ref-type="fig"}) upstream regulators were identified in IPA. [Table 4](#t4){ref-type="table"} shows the top upstream regulators using the common DEGs and [Table 5](#t5){ref-type="table"} lists the upstream regulators based on the unique DEGs for TPP, IPTP, and troglitazone. As expected, PPARG was the top common upstream regulator for all treatments. Interestingly, based on the unique DEGs for TPP there were only few upstream regulators identified ([Table 5A](#t5){ref-type="table"}). IPTP had many more upstream regulators identified in IPA from which the top ones based on the number of molecules involved are being listed ([Table 5B](#t5){ref-type="table"}). As expected, troglitazone had the most upstream regulators identified in IPA based on a much larger number of unique DEGs, and the top 10 are listed in [Table 5C](#t5){ref-type="table"}.

###### 

Top upstream regulators identified by IPA for TPP, IPTP, and troglitazone overlapping DEGs.

Table 4 lists upstream regulators in the first column; the corresponding molecule types and p-values are listed in the second and third columns, respectively.

  Upstream regulator     Molecule type                       *p*-Value
  ---------------------- ----------------------------------- -----------
  TPP, IPTP, MIDT                                             
   PPARG                 Ligand-dependent nuclear receptor   $< 0.001$
   NR1H2                 Ligand-dependent nuclear receptor   $< 0.001$
   GHRL                  Growth factor                       $< 0.001$
   Dihydrotestosterone   Chemical--endogenous mammalian      $< 0.001$
   FGF21                 Growth factor                       $< 0.001$
   LEP                   Growth factor                       $< 0.001$
   NR4A1                 Ligand-dependent nuclear receptor   $< 0.001$
   TNF                   Cytokine                            $< 0.001$

Note: Human primary preadipocytes were differentiated in the presence of MID supplemented with $20\;\mu M$ TPP, $20\;\mu M$ IPTP or $5\;\mu M$ troglitazone. At day 6 of differentiation, RNA was collected from five donors and used for RNA-seq. Genes that had $\geq + 1.5$ or $\leq - 1.5$ a fold change were uploaded into Venny version 2.0 for analysis and overlapping DEGs were uploaded into IPA. Only pathways containing more than five molecules are shown.

###### 

Top upstream regulators identified by IPA using unique DEGs to TPP, IPTP, and troglitazone.

Table 5 lists upstream regulator in the first column; the corresponding molecular type and p-value are listed in the other columns.

  Upstream regulator                               Molecule type                       *p*-Value
  ------------------------------------------------ ----------------------------------- ------------
  TPP                                                                                   
   DICER1                                          Enzyme                              $< 0.0001$
   miR-7155-5p (miRNAs w/seed CUGGGGU)             Mature microRNA                     $< 0.0001$
   miR-4667-5p (and other miRNAs w/seed CUGGGGA)   Mature microRNA                     $< 0.0001$
                                                                                        
  IPTP                                                                                  
   beta-Estradiol                                  Chemical--endogenous mammalian      $< 0.002$
   Lipopolysaccharide                              Chemical drug                       $< 0.002$
   Dexamethasone                                   Chemical drug                       $< 0.002$
   TNF                                             Cytokine                            $< 0.002$
   TGFB1                                           Growth factor                       $< 0.002$
   IFNG                                            Cytokine                            $< 0.002$
   ESR1                                            Ligand-dependent nuclear receptor   $< 0.002$
   TP53                                            Transcription regulator             $< 0.002$
   IL1B                                            cytokine                            $< 0.002$
                                                                                        
  Troglitazone                                                                          
   TP53                                            Transcription regulator             $< 0.0001$
   ERBB2                                           Kinase                              $< 0.0001$
   CCND1                                           Transcription regulator             $< 0.0001$
   TGFB1                                           Growth factor                       $< 0.0001$
   RB1                                             Transcription regulator             $< 0.0001$
   E2F4                                            Transcription regulator             $< 0.0001$
   CDKN1A                                          Kinase                              $< 0.0001$
   NUPR1                                           Transcription regulator             $< 0.0001$
   calcitriol                                      Chemical drug                       $< 0.0001$
   Vegf                                            Group                               $< 0.0001$

Note: Human primary preadipocytes were differentiated in the presence of MID supplemented with $20\;\mu M$ TPP, $20\;\mu M$ IPTP or $5\;\mu M$ troglitazone. At day 6 of differentiation, RNA was collected from five donors and used for RNA-seq. Genes that had $\geq + 1.5$ or $\leq - 1.5$ a fold change were uploaded into Venny version 2.0 for analysis and unique genes for TPP, IPTP, and troglitazone were uploaded into IPA. Data were sorted by number of molecules per pathway and only pathways containing more than three molecules for TPP and five molecules for IPTP and troglitazone are shown.

Discussion {#s4}
==========

We found that FM550, and its components TPP and IPTP, induce adipogenesis in human primary preadipocytes as demonstrated by lipid accumulation and expression of adipogenic markers. Further, we found that IPTP was able to increase lipid accumulation and FABP4 protein expression at lower concentrations than TPP. Our findings are in agreement with a previous study showing that treatment of murine pluripotent cells with the FM550 components TPP and IPTP diverted the cells to an adipogenic fate, as assessed by lipid accumulation and perilipin levels ([@c29]). However, ([@c29]) used an IPTP mixture containing 40% TPP and concluded that the main adipogenic component in FM550 was likely TPP. Here we show in human primary preadipocytes that an IPTP mixture containing only 18% TPP was more potent than pure TPP at inducing lipid accumulation and FABP4 expression.

The human preadipocyte differentiation model system allowed us to explore the mode of action of the chemicals of interest leading to adipogenesis and, potentially, obesity whether through PPARG activation or glucocorticoid pathways. Chemicals are tested for their ability to activate PPARG when replacing troglitazone in the differentiation medium and via the glucocorticoid pathway when chemicals are replacing dexamethasone. FM550 and its components, TPP and IPTP, are able to increase lipid accumulation in the presence of dexamethasone in human preadipocytes, although a positive trend, which did not reach statistical significance, was also observed in the presence of troglitazone for this end point in our study. It is very likely that statistical significance would have been achieved if more donors were used for the experiments. Using a murine model, others have shown that TPP and IPTP increased lipid accumulation; however, it is unclear which nuclear receptor these chemicals are targeting because murine cell models require either dexamethasone or troglitazone for differentiation ([@c11]). Our lipid accumulation data suggest that FM550, TPP, and IPTP may have other effects in addition to PPARG activation. Further, we have shown that in the murine 3T3-L1 model, the lipogenesis (lipid accumulation) mediated by dexamethasone TPP and IPTP was not inhibited by the PPARG antagonist GW9662, whereas troglitazone-mediated lipogenesis was ([@c36]). Moreover, in our study the test chemicals were added in the presence of $5\;\mu M$ troglitazone, a concentration by which PPARG is likely to be saturated ([@c25]) and unlikely to be further activated, supporting that mechanisms beyond PPARG activation are at work for lipogenesis. Therefore one may hypothesize that the glucocorticoid receptor may be a target. However, TPP and IPTP were not able to activate the glucocorticoid receptor in luciferase reporter assays (data not shown). Of further note, Pillai et al. ([@c29]) showed a modest increase in PPAR transactivation by TPP and IPTP relative to solvent control, and also showed that TPP was more potent than IPTP in mediating this effect. Therefore, these authors concluded that TPP was the adipogenic component in FM550 ([@c29]). Interestingly, we observed a higher PPARG transactivation in IPTP treatments compared with TPP treatments in luciferase assays (data not shown). Of importance, our mixture of isopropylated compounds (IPTP) contained only 18% TPP by analysis, whereas Pillai et al. ([@c29]) used a mixture containing 40%. Therefore, one may not conclude that TPP is the main PPARG activator in the FM550 mixture or that this is the only mechanism of action of the chemicals.

In addition to using a human model to assess the effects of FM550 components in inducing adipogenesis, we also performed global gene expression analysis to evaluate the mode of action of these chemicals. To the best of our knowledge, this study is the first to compare global transcriptomic changes in response to FM550 components in differentiating human preadipocyte or any other system. Interestingly, we found that IPTP treatment resulted in twice the number of affected DEGs as TPP. About half of the DEGs affected by IPTP were distinct (i.e., were not shared with either TPP or troglitazone). In contrast, most of the TPP-affected DEGs were in common with troglitazone treatment. This suggests that TPP acts mainly through PPARG activation, whereas IPTP perturbed a variety of regulatory pathways beyond just PPARG. Indeed, $\sim 84\%$ of the DEGs induced by TPP treatment were in common with DEGs induced by the PPARG agonist troglitazone, as opposed to 64% DEGs in common between IPTP and troglitazone.

When we assessed the transcript levels of select DEGs by RT-qPCR, we found striking differences between the three treatments. The fold change in the expression of some DEGs was larger in the TPP treatment versus the IPTP treatment, and *vice versa*. For example, *PCK1*, *PLIN4*, and *FABP5* were all increased to a greater extent by TPP. All these genes are involved in lipogenesis, an integral part of adipocyte differentiation ([@c8]). Interestingly, IPTP treatment induced higher expression levels of transporters, such as *ABCG1* and *SLCO4C1* than TPP. ABCG1 expression is positively correlated with triglyceride accumulation during adipogenesis by increasing fatty acid influx ([@c10]). Fatty acids are known to act as endogenous PPARG agonists ([@c18]), and therefore this may be a plausible mechanism by which these chemicals indirectly activate PPARG. SLCO4C1 is a member of the transporter superfamily mediating the transport of thyroid hormones, $T_{3}$ and $T_{4}$ ([@c37]). It has been shown that when preadipocytes are transduced with an inactive thyroid hormone receptor mutant a decrease in the expression of adipogenic markers is observed ([@c23]). This suggests that increased intracellular thyroid hormone levels, which may be mediated by SLCO4C1, enhance human adipogenesis.

The distinct effects observed in the TPP and IPTP treatments are also apparent in the canonical pathways enriched in IPA. For TPP treatment, many of the pathways were in common with the troglitazone treatment, as expected, although some were unique. Of those, protein kinase A signaling is relevant, as it is elevated early in adipogenesis ([@c17]). During a standard differentiation protocol, IBMX is used to increase intracellular cAMP concentrations, which in turn activates PKA ([@c30]). Because all treatments contained IBMX, a phosphodiesterase inhibitor, it is remarkable that only TPP further increased this process. Another relevant pathway that was enriched in TPP treatment was AMPK Signaling, which is involved in energy metabolism and fatty acid oxidation ([@c12]). Some of the IPTP perturbed pathways included caveolar-mediated endocytosis signaling and clathrin-mediated endocytosis signaling, both of which are involved in insulin receptor and solute carrier family 2 (facilitated glucose transporter), member 4 (GLUT4) endocytosis, respectively ([@c9]; [@c22]). In addition, IPTP also affected the paxillin signaling pathway, which is involved in cytoskeletal remodeling, an important process in adipocyte differentiation ([@c16]; [@c26]). This further indicates that although both chemicals may modulate adipogenesis, their modes of action may be different.

The top upstream regulators identified by IPA for all treatments are known regulators of the adipogenic process. With respect to these identified regulators, the mode of action of TPP appears to resemble the mode of action of troglitazone. In addition, the few upstream regulators that were identified in IPA using the unique DEGs to TPP did not appear to have any known function in adipogenesis. However, for IPTP dexamethasone was identified as one of the top upstream regulators using unique DEGs. Of note, CEBPA, an important transcription factor in adipogenesis was identified as an upstream regulator in TPP and troglitazone-treated cells (not in the top 10) but not in IPTP. In addition, CEBPA was not a DEG identified in the IPTP treatment; however, this may be due to the delayed increase in mRNA expression of CEBPA by IPTP treatment, which reached significance only at day 9 ([Figure 3](#f3){ref-type="fig"}). This is not surprising considering that the mRNA used in the RNA-seq analysis was obtained at an earlier time point (day 6). This is one limitation of this study, where we chose one most potent concentration and one time point to generate the data due to prohibiting costs. Further, the concentration of FM550 and its components used in this study were in the $\mu M$ range, whereas human exposure is estimated at the nM range. However, it is difficult to extrapolate *in vitro* doses to human exposure. First, human exposure is chronic and some of the chemicals may have lipophilic properties and may be accumulative in tissues, including the fat tissue. In fact, accumulation of FM550 components was detected in the blubber of some marine species, showing that these compounds may accumulate in adipose tissue ([@c19]). In addition, chemicals may adhere to the plastic or media components *in vitro*, and therefore the intracellular concentrations may be different than the ones applied. More knowledge is needed on the pharmacokinetics of FM550 and its components in humans and in cell culture in order to be able to model how the doses used *in vitro* correlate to the *in vivo* exposure. Future studies will focus on DEGs of interest to establish the mode of action of TPP and IPTP in more depth.

Conclusion {#s5}
==========

In conclusion, we demonstrated that FM550 and its components, TPP and IPTP, induced adipogenesis in human primary preadipocytes *in vitro*. Although others have concluded that TPP is the main adipogenic component in FM550 and an activator of PPARG in a murine model system, using the human model we show that IPTP is also adipogenic. Global gene expression profiles revealed that both components had a gene signature that supported an adipogenic end point. However, of the two, TPP seemed to have a mode of action more similar to that of a known PPARG agonist. Interestingly, IPTP exhibited a more distinct gene profile from the PPARG agonist. Taken together, we show that although both components of FM550 increase human adipocyte differentiation, they may also exert other effects via different mechanisms. Overall, the results of this study suggest that human exposure to FM550 may promote adverse metabolic effects and as such, further investigation into the mechanisms of action of these chemicals is needed.
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